PCM
ARLZ

Prelude Capital Management’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Prelude Capital Management’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,100
Closed -$3K – 2134
2017
Q2 		$3K Sell
2,100
-26,900
-93% -$38.9K ﹤0.01% 1518
2017
Q1 		$62K Buy
29,000
+4,000
+16% +$15K 0.01% 915
2016
Q4 		$110K Buy
25,000
+12,600
+102% +$59.8K 0.01% 800
2016
Q3 		$60K Buy
+12,400
New +$56.5K 0.01% 991

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

Prelude Capital Management's ARLZ Position: Q3 2017 in Review

Prelude Capital Management sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2017, closing a stake of 2,100 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in ARLZ in Q3 2016 and held it in 4 quarters. The position peaked at $110K in Q4 2016. 59 funds tracked by Wall St. Rank hold ARLZ as of Q3 2017.

  • Prelude Capital Management reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2017 after selling out during the quarter.
  • Prelude Capital Management sold 2,100 Aralez Pharmaceuticals Inc. shares in Q3 2017, an estimated $3K.
  • Prelude Capital Management first reported a position in Aralez Pharmaceuticals Inc. in Q3 2016 and held it in 4 quarters.
  • Prelude Capital Management's Aralez Pharmaceuticals Inc. position peaked at $110K in Q4 2016.
  • 59 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2017.

Based on Prelude Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.